Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Adalta’s (1AD) competitive prospects improved recently when a high profile drug, ziritaxestat, being developed by Galapagos and Gilead Sciences for idiopathic pulmonary fibrosis (IPF), was discontinued.
Pages